In 922 patients with HFrEF due to Chagas disease, sacubitril/valsartan vs enalapril won the hierarchical primary outcome (win ratio 1.52), driven by NT-proBNP fall; cardiovascular death (23.8% vs 25.4%) and HF admission did not differ significantly.
RCTn = 922
Lopes et al. Sacubitril/Valsartan vs Enalapril in Heart Failure Due to Chagas Disease: An Open-Label, Multicenter Randomized Clinical Trial